Detalhe da pesquisa
1.
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
J Clin Oncol;
22(23): 4622-30, 2004 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15505276
2.
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
J Clin Oncol;
22(15): 3070-9, 2004 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15284257
3.
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
J Clin Oncol;
24(7): 1127-35, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16505432